Apical barriers to airway epithelial cell gene transfer with amphotropic retroviral vectors.
Gene transfer to airway epithelia with amphotropic pseudotyped retroviral vectors is inefficient following apical vector application. To better understand this inefficiency, we localized the expression of Pit2, the amphotropic receptor, in polarized human airway epithelia. Pit2 was expressed on both the apical and basolateral surfaces of the cells, suggesting that factors other than receptor abundance may limit apical gene transfer efficiency. Binding studies performed with radiolabeled amphotropic MuLV suggested that the apically applied virus binds to Pit2. Hypothetical barriers to retroviral gene transfer include the apical glycocalyx and other secreted products of epithelia. In this study, we demonstrated that sialic acid, keratan sulfate and collagen type V are present on the apical surface of well-differentiated human airway epithelia. While enzyme treatment reduced the abundance of these components, the treatment also decreased the transepithelial resistance to approximately 35% of the controls, suggesting that the epithelial integrity was impaired. To attain an airway epithelial culture with a modified apical surface and intact epithelial integrity, we utilized 100 mM 2-deoxy-D-glucose, a glycosylation inhibitor, to prevent the glycocalyx from reforming following enzyme treatment. This approach allowed the resistance, but not the apical glycocalyx to recover. Despite this physical modification of the cell surface, the amphotropic retroviral vector failed to transduce airway epithelia following apical application. These results suggest that factors other than apical receptor abundance and the glycocalyx inhibit amphotropic retroviral gene transfer in human airway epithelia.
Wang
G
G
Program in Gene Therapy, Department of Pediatrics, University of Iowa College of Medicine, Iowa City, IA 52242, USA.
Williams
G
G
Xia
H
H
Hickey
M
M
Shao
J
J
Davidson
B L
BL
McCray
P B
PB
D016764:Cell Polarity; D002478:Cells, Cultured; D003550:Cystic Fibrosis / Q000628:therapy*; D004268:DNA-Binding Proteins / Q000032:analysis / Q000378:metabolism; D004847:Epithelial Cells / Q000378:metabolism / Q000648:ultrastructure; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage*; D019276:Glycocalyx / Q000648:ultrastructure; D006801:Humans; D008854:Microscopy, Electron; D008855:Microscopy, Electron, Scanning; D008979:Moloney murine leukemia virus / Q000235:genetics*; D011485:Protein Binding; D020545:Respiratory Mucosa / Q000166:cytology* / Q000648:ultrastructure; D050817:Transcription Factor Pit-1; D014157:Transcription Factors / Q000032:analysis / Q000378:metabolism; D014161:Transduction, Genetic / Q000379:methods; D001616:beta-Galactosidase / Q000235:genetics
D004268:DNA-Binding Proteins; C494187:POU1F1 protein, human; D050817:Transcription Factor Pit-1; D014157:Transcription Factors; D001616:beta-Galactosidase